A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow- up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of immune response of a Herpes Zoster subunit vaccine and assessment of persistence of immune response and safety of 1 or 2 additional doses administered in ZOSTER-049 in 2 subgroups of older adults.

Herpes Zoster

Confirmed HZ cases during the total duration of the ZOSTER-101 study (Day 1 through Month 48).

Confirmed HZ cases since 1-month post Dose 2 in the ZOSTER-006/022 studies until the end of the ZOSTER- 101 study., Anti-gE antibody concentrations at Day 1*, Months 12, 24, 36 and 48 in ZOSTER-101 study., Frequency of gE-specific CD4+ T-cells secreting at least 2 activation markers (from among IFN-γ, IL-2, TNF-α, CD40L) at Day 1*, Months 12, 24, 36 and 48 in ZOSTER-101 study., Number and percentage of participants with SAEs which are assessed as causally related to the study intervention by the investigator during the total duration of the ZOSTER-101 study (Day 1 through Month 48)., Number and percentage of participants with pIMDs (serious and non-serious) which are assessed as causally related to the study intervention by the investigator during the total duration of the ZOSTER- 101 study (Day 1 through Month 48)., Number and percentage of participants with HZ-related complications of confirmed HZ during the total duration of the ZOSTER-101 study (Day 1 through Month 48).

No related papers found yet.

Czechia, Estonia, Finland, France, Germany, Italy, Spain, Sweden